Nonalcoholic steatohepatitis: what we know in the new millennium - PubMed (original) (raw)
Review
Nonalcoholic steatohepatitis: what we know in the new millennium
Stephen A Harrison et al. Am J Gastroenterol. 2002 Nov.
Abstract
Nonalcoholic steatohepatitis (NASH) is a liver disease characterized by diffuse fatty infiltration and inflammation. The exact prevalence of NASH is unclear, but it is becoming more evident that the disease is much more common than previously thought. Although generally a benign, indolent process, it can progress to advanced liver disease in approximately 15-20% of patients. Clinical characteristics associated with NASH include obesity, hyperlipidemia, diabetes mellitus, and hypertension, all of which have been associated with underlying insulin resistance. Typically, this disease becomes evident in the fourth or fifth decade of life with an equal sex predilection. NASH is thought to be caused, in part, by impaired insulin signaling, leading to elevated circulating insulin levels and subsequent altered lipid homeostasis. This process is likely multifactorial and includes both genetic and environmental factors. Treatment options to date are limited and are based on very small clinical trials. Current investigations are focusing on improving the underlying insulin resistance that has been associated with NASH as well as other therapies that decrease oxidative stress or improve hepatocyte survival.
Similar articles
- Non-alcoholic steatohepatitis in children.
Nanda K. Nanda K. Pediatr Transplant. 2004 Dec;8(6):613-8. doi: 10.1111/j.1399-3046.2004.00241.x. Pediatr Transplant. 2004. PMID: 15598336 Review. - Diabetes mellitus, obesity, and hepatic steatosis.
Youssef W, McCullough AJ. Youssef W, et al. Semin Gastrointest Dis. 2002 Jan;13(1):17-30. Semin Gastrointest Dis. 2002. PMID: 11944630 Review. - [Nonalcoholic steatohepatitis: pathogenesis and treatment].
Park SH. Park SH. Korean J Hepatol. 2008 Mar;14(1):12-27. doi: 10.3350/kjhep.2008.14.1.12. Korean J Hepatol. 2008. PMID: 18367854 Review. Korean. - [Non-alcoholic fatty liver disease--new view].
Raszeja-Wyszomirska J, Lawniczak M, Marlicz W, Miezyńska-Kurtycz J, Milkiewicz P. Raszeja-Wyszomirska J, et al. Pol Merkur Lekarski. 2008 Jun;24(144):568-71. Pol Merkur Lekarski. 2008. PMID: 18702346 Review. Polish. - [Nonalcoholic steatohepatitis--a "new" hepatic disease].
Grønbaek H, Eivindson MV, Hamilton-Dutoit S, Vilstrup H. Grønbaek H, et al. Ugeskr Laeger. 2003 Mar 10;165(11):1115-8. Ugeskr Laeger. 2003. PMID: 12677985 Review. Danish.
Cited by
- Liver-specific Coxsackievirus and adenovirus receptor deletion develop metabolic dysfunction-associated fatty liver disease.
Kim HG, Park JH, Shin HH, Kim SH, Jeon HE, Shin JH, Won YS, Kwon HJ, Jeon ES, Lim BK. Kim HG, et al. Sci Rep. 2024 Sep 16;14(1):21642. doi: 10.1038/s41598-024-72561-2. Sci Rep. 2024. PMID: 39285218 Free PMC article. - Nonalcoholic Fatty Liver Disease: Changes in Gut Microbiota and Blood Lipids.
Yang K, Zeng J, Wu H, Liu H, Ding Z, Liang W, Wu L, Lin Z, Huang W, Xu J, Dong F. Yang K, et al. J Clin Transl Hepatol. 2024 Apr 28;12(4):333-345. doi: 10.14218/JCTH.2023.00199. Epub 2024 Mar 18. J Clin Transl Hepatol. 2024. PMID: 38638378 Free PMC article. - Histological findings and NAFLD/NASH Status in liver biopsies of patients subjected to bariatric surgery.
Malucelli M, Strobel R, Ivantes C, Sakamoto D, Luís Duarte M, Lucia Alves Pedroso M. Malucelli M, et al. Arch Endocrinol Metab. 2023 Nov 10;68:e220138. doi: 10.20945/2359-4292-2022-0138. Arch Endocrinol Metab. 2023. PMID: 37948562 Free PMC article. - ATP citrate lyase inhibitor Bempedoic Acid alleviate long term HFD induced NASH through improvement in glycemic control, reduction of hepatic triglycerides & total cholesterol, modulation of inflammatory & fibrotic genes and improvement in NAS score.
Sanjay KV, Vishwakarma S, Zope BR, Mane VS, Mohire S, Dhakshinamoorthy S. Sanjay KV, et al. Curr Res Pharmacol Drug Discov. 2021 Sep 4;2:100051. doi: 10.1016/j.crphar.2021.100051. eCollection 2021. Curr Res Pharmacol Drug Discov. 2021. PMID: 34909677 Free PMC article. - Seroprevalence and risk factors of hepatitis B and C viruses among diabetes mellitus patients in Duhok province, Iraqi Kurdistan.
Merza MA. Merza MA. J Family Med Prim Care. 2020 Feb 28;9(2):642-646. doi: 10.4103/jfmpc.jfmpc_1158_19. eCollection 2020 Feb. J Family Med Prim Care. 2020. PMID: 32318396 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources